J Physiol Wellcome Trust-funded researchers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 574, Number 1, 149-166, July 1, 2006 DOI: 10.1113/jphysiol.2006.107904
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
574/1/149    most recent
jphysiol.2006.107904v1
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sala-Rabanal, M.
Right arrow Articles by Wright, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sala-Rabanal, M.
Right arrow Articles by Wright, E. M.
Related Collections
Right arrow Molecular and Genomic

MOLECULAR AND GENOMIC

Molecular interactions between dipeptides, drugs and the human intestinal H+–oligopeptide cotransporter hPEPT1

Monica Sala-Rabanal1, Donald D. F. Loo1, Bruce A. Hirayama1, Eric Turk1 and Ernest M. Wright1

1 Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1751, USA

The human intestinal proton-coupled oligopeptide transporter hPEPT1 has been implicated in the absorption of pharmacologically active compounds. We have investigated the interactions between a comprehensive selection of drugs, and wild-type and variant hPEPT1s expressed in Xenopus oocytes, using radiotracer uptake and electrophysiological methods. The ß-lactam antibiotics ampicillin, amoxicillin, cephalexin and cefadroxil, the antineoplastics {delta}-aminolevulinic acid ({delta}-ALA) and bestatin, and the neuropeptide N-acetyl-Asp-Glu (NAAG), were transported, as judged by their ability to evoke inward currents. When the drugs were added in the presence of the typical substrate glycylsarcosine (Gly-Sar), the inward currents were equal or less than that induced by Gly-Sar alone. This suggests that the drugs are transported at a lower turnover rate than Gly-Sar, but may also point towards complex interactions between dipeptides, drugs and the transporter. Gly-Sar and the drugs also modified the kinetics of hPEPT1 presteady-state charge movement, by causing a reduction in maximum charge (Qmax) and a shift of the midpoint voltage (V0.5) to more negative potentials. Our results indicate that the substrate selectivity of hPEPT1 is: Gly-Sar > NAAG, {delta}-ALA, bestatin > cefadroxil, cephalexin > ampicillin, amoxicillin. Based on steady-state and presteady-state analysis of Gly-Sar and cefadroxil transport, we proposed an extension of the 6-state kinetic model for hPEPT1 function that globally accounts for the observed presteady-state and steady-state kinetics of neutral dipeptide and drug transport. Our model suggests that, under saturating conditions, the rate-limiting step of the hPEPT1 transport cycle is the reorientation of the empty carrier within the membrane. Variations in rates of drug cotransport are predicted to be due to differences in affinity and turnover rate. Oral availability of drugs may be reduced in the presence of physiological concentrations of dietary dipeptides in the gut, suggesting that oral delivery drugs should be taken on an empty stomach. The common hPEPT1 single-nucleotide polymorphisms Ser117Asn and Gly419Ala retained the essential kinetic and drug recognition characteristics of the wild type, suggesting that neither variant is likely to have a major impact on oral absorption of drugs.

(Received 16 February 2006; accepted after revision 13 April 2006; first published online 20 April 2006)
Corresponding author M. Sala-Rabanal: Department of Physiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 53-330 CHS, Los Angeles, California 90095-1751, USA. Email: msala{at}mednet.ucla.edu




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. Krige, L. A. Needham, L. J. Bawden, N. Flores, H. Farmer, L. E.C. Miles, E. Stone, J. Callaghan, S. Chandler, V. L. Clark, et al.
CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
Cancer Res., August 15, 2008; 68(16): 6669 - 6679.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Sala-Rabanal, D. D. F. Loo, B. A. Hirayama, and E. M. Wright
Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2
Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1422 - F1432.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. Miszner, A. Peres, M. Castagna, S. Bette, S. Giovannardi, F. Cherubino, and E. Bossi
Structural and functional basis of amino acid specificity in the invertebrate cotransporter KAAT1
J. Physiol., June 15, 2007; 581(3): 899 - 913.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Physiol.Home page
D. D.F. Loo, B. A. Hirayama, M. H. Karakossian, A.-K. Meinild, and E. M. Wright
Conformational Dynamics of hSGLT1 during Na+/Glucose Cotransport
J. Gen. Physiol., December 1, 2006; 128(6): 701 - 720.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 The Physiological Society.